First and only immunotherapy to demonstrate survival benefit in this setting in a global Phase III trial
First and only AKT inhibitor approved in Japan for breast cancer patients with specific biomarker alterations
Submission to be reviewed under FDA real-time oncology review and Project Orbis
Dapagliflozin and Saxagliptin Tablets (RLD Qtern) had estimated annual sales of US $5 million in the US
The company has received five final approvals
US FDA approval based on NEURO-TTRansform Phase III results
The product is expected to be launched in FY25
Dapagliflozin Tablets (RLD Farxiga) had estimated annual sales of USD 7282 million in the US
First-in-class AKT inhibitor has potential to reshape treatment for breast cancer patients
Approval based on results from TOPAZ-1 global Phase III trial and a Chinese patient
Subscribe To Our Newsletter & Stay Updated
